Latest Orion Pharma News & Updates

See the latest news and media coverage for Orion. We track all announcements, press releases, and industry mentions in real time, all in one place.

Orion Pharma (Orion)

Nordic pharmaceutical company developing human and veterinary medicines

orionpharma.com

Headquarters: Espoo, Finland
Company type: Public company
Number of employees: 3,600–5,000
Industry: Pharmaceuticals

Last updated October 28

Latest news about Orion Pharma (Orion)

In short: Orion delivered strong 2026 results, raised its outlook, and advanced prostate cancer data and biosimilar partnerships.

Company announcements

October 28 Orion

Orion reports strong Q3 results and executive team changes

Growth was driven by an increase in Nubeqa® sales. The presentation also includes a forecast for 2026 and information on clinical development programs.

October 20 Orion

Orion upgrades its full-year financial outlook for 2026

The company raised net sales and operating profit estimates due to stronger-than-expected royalty income growth in the first nine months.

September 30 Orion

Orion completed its own share buyback

The company purchased 500,000 Class B shares at an average price of approximately EUR 80.98, for a total of EUR 40.5 million.

September 4 Orion

Orion purchases 102722 shares totaling EUR 48 million last week

The acquisition fulfills part of the company announced a share buyback programme running until December 31. Total treasury holdings now reach 370,888 Class B shares.

Media coverage

October 28 MarketScreener

Orion Group Interim report January-September 2026: Strong financial performance and positive developments in the R&D pipeline

"We delivered a strong third quarter, with revenue growth driven by the Innovative Medicines and Branded Products business divisions. Profitability improved mostly due to an...

October 24 Finanznachrichten

Orion: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in...

October 20 Kauppalehti

Inside information: Orion upgrades full-year outlook for 2026

INSIDE INFORMATION 20 OCTOBER 2026 at 20.20 EEST. Inside information: Orion upgrades full-year outlook for 2026. Orion Corporation upg ...

October 6 Yahoo Finance

Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market

ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion...

Never miss news about Orion

Track Orion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Orion competitors & trending companies

Browse news for competitors to Orion and other trending companies.